Prolonged Suppression of Human Immunodeficiency Virus Type 1 (HIV‐1) Viremia in Persons with Advanced Disease Results in Enhancement of CD4 T Cell Reactivity to Microbial Antigens but Not to HIV‐1 Antigens
Citations Over TimeTop 10% of 1999 papers
Abstract
CD4 T cell responses were studied for >2 years in 27 zidovudine-experienced patients with advanced human immunodeficiency virus type 1 (HIV-1) infection who received triple combination drug therapy with indinavir, zidovudine and lamivudine or zidovudine plus lamivudine or zidovudine alone for 24-42 weeks before switching to the three-drug therapy. Subjects initially given the three drugs had viremia suppressed to undetectable levels and increases in T cell proliferative and cytokine responses to microbial antigens through 2 years of follow-up. Patients receiving the triple-drug therapy after either indinavir or zidovudine-lamivudine treatment had similar increases in T cell responses only if they also had suppression of virus load. CD4 T cell reactivity to HIV-1 antigens was not restored. Prolonged indinavir-zidovudine-lamivudine treatment has significant but incomplete enhancing effects on CD4 T cell reactivity, which could be important in host control of microbial and persistent HIV-1 infections.
Related Papers
- → Extensive characterization of HIV-1 reservoirs reveals links to plasma viremia before and during analytical treatment interruption(2022)32 cited
- Intermittent low-level viremia in very early primary HIV-1 infection.(2005)
- → Viremic Responses of Genetically Susceptible and Resistant Chickens to Experimental Infection with Acute, Mild, or Both Strains of Marek's Disease Herpesvirus(1975)9 cited
- → Studies of Turkey Herpesvirus Viremia in Two Strains of Vaccinated Chickens: Strain Difference and Effects of Vaccine Dose(1977)12 cited